Here’s the uncomfortable truth abouttraditional testosterone replacement therapy: it works brilliantly for raisingtestosterone levels, but it effectively shuts down your body’s own production.For men who aren’t concerned about fertility, this trade-off is oftenacceptable. But for men in their 20s, 30s, or early 40s who may want to fatherchildren — now or in the future — it creates a genuine dilemma.
Exogenous testosterone suppresses thehypothalamic-pituitary-gonadal (HPG) axis. When the body detects sufficienttestosterone from an external source, it stops sending the signals (LH and FSH)that tell the testes to produce both testosterone and sperm. The result can bedramatically reduced sperm counts — sometimes to zero.
Enclomiphene solves this problem. It booststestosterone by working with your body’s own production system rather thanreplacing it — and it’s one of the key medications in Luvo’s testosteroneprogram.
Enclomiphene is the trans-isomer of clomiphenecitrate, a medication that has been used in fertility medicine for decades.What makes Enclomiphene special is its targeted mechanism of action.
In the male hormonal system, the hypothalamusmonitors testosterone levels via estrogen signaling. When estrogen (convertedfrom testosterone via aromatase) reaches certain levels, it tells thehypothalamus to reduce GnRH (gonadotropin-releasing hormone) output. Thisreduces LH and FSH from the pituitary, which in turn reduces testiculartestosterone production. It’s a negative feedback loop.
Enclomiphene works by selectively blockingestrogen receptors in the hypothalamus. The hypothalamus, now “blind” toestrogen feedback, interprets the situation as low testosterone and responds byincreasing GnRH output. This stimulates the pituitary to release more LH andFSH, which stimulates the testes to produce more testosterone and maintainsperm production.
The result is elevated testosterone throughyour body’s own machinery, with fully preserved — and often enhanced —fertility. Your testes stay active, your sperm production continues, and yourHPG axis remains functional.
If you’ve researched testosteroneoptimization, you may have encountered clomiphene citrate (Clomid). Clomipheneis a mixture of two isomers: enclomiphene (the trans-isomer) and zuclomiphene(the cis-isomer). They have very different properties.
Enclomiphene is the therapeutically activeisomer responsible for the testosterone-boosting effects. It has a relativelyshort half-life and clean pharmacological action on estrogen receptors in thehypothalamus.
Zuclomiphene, by contrast, has estrogenicactivity in some tissues and a much longer half-life, meaning it accumulateswith repeated dosing. This accumulation is believed to be responsible for manyof the side effects associated with clomiphene citrate, including visualdisturbances, mood changes, and paradoxical estrogenic effects.
By using pure Enclomiphene rather than mixedclomiphene, Luvo’s program delivers the testosterone-boosting benefit withoutthe baggage of zuclomiphene accumulation. This is a meaningful clinicaladvantage that many competitors either don’t offer or don’t explain.
Enclomiphene is particularly well-suited forseveral patient profiles.
Younger men with low testosterone who want topreserve fertility are the primary candidates. If you’re under 40 and may wantchildren in the future, Enclomiphene offers testosterone optimization withoutcompromising reproductive potential.
Men with secondary hypogonadism — where theproblem is inadequate signaling from the pituitary rather than testicularfailure — are ideal candidates because Enclomiphene specifically addresses thesignaling deficit.
Men who prefer a non-injectable option mayfind Enclomiphene appealing, as it’s taken orally rather than by injection.
Men who want to try a conservative approachbefore committing to TRT can use Enclomiphene as a first step. If it raisestestosterone sufficiently and resolves symptoms, TRT may not be necessary.
Enclomiphene is less likely to be sufficientfor men with primary hypogonadism (testicular failure) or men with very lowtestosterone who need the more robust elevation that TRT provides. In thesecases, Luvo’s providers may recommend TRT with Gonadorelin to maintainfertility.
Explore Luvo’s Enclomiphene option or the fulltestosterone program.
Clinical data on Enclomiphene demonstratesconsistent testosterone elevation. Studies have shown that Enclomiphene canincrease total testosterone by 150–300 ng/dL on average, often bringing menfrom the low or low-normal range into the mid-to-upper normal range.
Patients typically notice improvements inenergy and mood within 2–4 weeks as testosterone levels rise. Libidoimprovements often follow within 4–8 weeks. Body composition changes developmore gradually over 2–6 months, similar to the timeline with TRT thoughsometimes more modest depending on the degree of testosterone elevationachieved.
Sperm parameters are maintained or improvedthroughout treatment — a critical difference from TRT. Some studies have shownincreases in sperm concentration and motility during Enclomiphene therapy,making it a dual-purpose treatment for men dealing with both low T andsubfertility.
Your Luvo provider will monitor yourtestosterone levels, symptoms, and response to ensure Enclomiphene isdelivering the results you need. If it’s not sufficient, transitioning to TRTwith Gonadorelin support remains an option.
Ask most men on testosterone replacementtherapy about fertility preservation and you’ll get a blank look. Ask theirproviders, and you might get a shrug. The reality is that many TRT protocols —especially those from high-volume telehealth clinics — prescribe testosteronewithout addressing one of its most significant consequences: suppression of thebody’s own reproductive signaling.
When you take exogenous testosterone, yourpituitary gland reduces production of luteinizing hormone (LH) andfollicle-stimulating hormone (FSH). Without LH, the testes reduce their owntestosterone production. Without FSH, sperm production declines. For some men,this means testicular atrophy and near-zero sperm counts within months ofstarting TRT.
Gonadorelin is the solution to this problem,and it’s a core component of Luvo’s testosterone program. Here’s why itmatters.
Gonadorelin is a synthetic analog ofgonadotropin-releasing hormone (GnRH) — the hormone naturally produced by thehypothalamus to signal the pituitary gland. When administered in pulsatilefashion (mimicking the body’s natural release pattern), Gonadorelin stimulatesthe pituitary to produce LH and FSH.
This is significant during TRT becauseexogenous testosterone suppresses GnRH from the hypothalamus. The pituitary,receiving no GnRH signal, stops producing LH and FSH. Gonadorelin replaces thismissing signal, keeping the pituitary active and maintaining downstream gonadalfunction.
The result is that the testes continue toproduce sperm and contribute their own testosterone, even while exogenoustestosterone is being administered. Testicular volume is maintained, and theHPG axis remains functional rather than being completely suppressed.
This mechanism makes Gonadorelin fundamentallydifferent from hCG (human chorionic gonadotropin), which was historically usedfor this purpose. While hCG mimics LH directly at the testicular level,Gonadorelin works upstream at the pituitary — preserving the entire signalingcascade rather than just one step of it.
Many men starting TRT in their 30s or 40s saythey’re “done having kids” or “not planning on it.” While that may be truetoday, life circumstances change. Relationships change. Decisions that seemedpermanent at 35 look different at 42.
Beyond future fertility, there are otherreasons to maintain testicular function during TRT.
Testicular atrophy is cosmetically andpsychologically significant for many men. The reduction in testicular size thatoccurs with unsupported TRT is noticeable and can affect self-image andconfidence — ironic for a therapy meant to improve exactly those things.
Intratesticular testosterone productioncontributes to local tissue health beyond just sperm production. The testesproduce hormones and signaling molecules that support the broader reproductivesystem.
HPG axis preservation makes it easier todiscontinue TRT if you ever choose to. Without Gonadorelin, prolonged TRT candeeply suppress the HPG axis, making recovery of natural testosteroneproduction difficult and prolonged. With Gonadorelin maintaining pituitaryfunction, the transition off TRT is smoother.
Luvo’s program includes Gonadorelin as astandard consideration for men on TRT precisely because these benefits extendfar beyond just fertility.
Luvo’s testosterone program offers Gonadorelinas a key adjunct therapy for men on TRT. The typical protocol involvessubcutaneous injection administered multiple times per week, timed to providethe pulsatile stimulation the pituitary needs.
Your Luvo provider determines the appropriateGonadorelin protocol based on your specific situation, including your age,fertility goals, baseline hormonal status, and the testosterone dose you’rereceiving.
The combination of testosterone medication andGonadorelin gives you the benefits of testosterone optimization withoutsacrificing reproductive function — a combination that competitors like Hims,Willow, and Found rarely offer as an integrated protocol.
For men who want to optimize testosterone withoutexogenous testosterone at all, Gonadorelin can also be used alongsideEnclomiphene for a fully endogenous approach that stimulates the body’s ownproduction from both the pituitary and hypothalamic levels.
Learn more about Gonadorelin at Luvo, or explorethe complete testosterone program.
Is Gonadorelin the same as hCG? No.Gonadorelin is a GnRH analog that works at the pituitary level, while hCGmimics LH at the testicular level. Gonadorelin preserves the full HPG signalingcascade, which many clinicians consider a more physiological approach.Additionally, hCG has faced supply and regulatory challenges in recent years,making Gonadorelin an increasingly preferred alternative.
Does Gonadorelin have side effects? Sideeffects are generally mild. Injection-site reactions are the most common. Somemen experience mild headaches or temporary discomfort at the injection site.Serious adverse effects are rare at the doses used for fertility preservation.
Can Gonadorelin fully prevent fertility losson TRT? While no intervention provides a 100% guarantee, Gonadorelinsignificantly mitigates the suppressive effects of TRT on sperm production.Most men maintain meaningful sperm counts when Gonadorelin is used consistentlyalongside TRT.
How long do I need to take Gonadorelin?Typically, for as long as you’re on TRT and want to maintain testicularfunction and fertility potential. Your Luvo provider will guide this decisionbased on your evolving goals and clinical status.
For many men, the 40s are when theaccumulation of declining testosterone becomes impossible to ignore. Thesymptoms that were subtle in your late 30s — a little more fatigue, a littleless drive — become hard to dismiss by 42 or 45. The belly fat that resistedyour best efforts, the gym sessions that stopped producing results, the libidothat shifted from a priority to an afterthought, the mental sharpness that usedto be effortless.
Here’s the good news: this is one of the mosttreatable conditions in medicine. Testosterone optimization in men over 40 issafe, effective, and increasingly well-supported by clinical evidence. AndLuvo’s testosterone program is specifically designed to make it accessible,affordable, and clinically supervised.
By age 40, most men have experienced a 15–25%decline from their peak testosterone levels. By 50, that decline often reaches30–40%. But the numbers only tell part of the story.
SHBG (sex hormone-binding globulin) tends toincrease with age, binding more of your circulating testosterone and reducingthe free testosterone available to your tissues. This means your totaltestosterone number may underestimate the actual deficiency your body isexperiencing. A man with a total testosterone of 450 ng/dL but elevated SHBGmay have the free testosterone equivalent of someone at 300 ng/dL.
Additionally, androgen receptor sensitivitymay decline with age, meaning the same testosterone level produces lessbiological effect in a 50-year-old than a 30-year-old. Your tissues become lessresponsive to the hormone even as less of it is available.
The result is that men over 40 often feel theeffects of testosterone decline more acutely than their numbers alone wouldsuggest. This is why Luvo’s providers assess the full hormonal picture — totaltestosterone, free testosterone, SHBG, LH, FSH, and estradiol — rather than makingdecisions based on a single number.
A persistent myth in some medical circlesholds that testosterone therapy in older men is unnecessary or risky. Neitherclaim holds up under current evidence.
The TRAVERSE trial, published in the NewEngland Journal of Medicine, studied over 5,000 men aged 45–80 withhypogonadism and pre-existing cardiovascular disease or high cardiovascularrisk. The study found no increased cardiovascular risk with testosteronetherapy — directly contradicting the fears that kept many providers fromprescribing TRT to older men.
The Testosterone Trials (TTrials), acoordinated set of seven randomized controlled trials in men over 65,demonstrated that testosterone therapy improved sexual function, physicalfunction (walking distance), vitality, mood, and bone density. These benefitswere consistent and clinically meaningful.
The evidence is clear: age alone is not acontraindication to testosterone optimization. What matters is whether you havea documented deficiency, whether you have symptoms that affect your quality oflife, and whether appropriate screening and monitoring are in place.
Luvo’s program provides all three. Competitorsthat turn away men over 40 or 50 are operating on outdated science.
While the benefits of testosteroneoptimization apply across age groups, men over 40 may have specificconsiderations that influence treatment planning.
Fertility priorities shift for many men over40, but not all. Some men in their 40s and even 50s are starting new families.Luvo’s availability of Enclomiphene and Gonadorelin ensures that fertilitypreservation remains an option regardless of age.
Prostate health monitoring becomes more important.While testosterone therapy does not cause prostate cancer, pre-existingprostate conditions should be evaluated before starting treatment. Luvo’sprotocol includes baseline PSA testing and regular monitoring.
Cardiovascular risk factors are more prevalentin men over 40. Luvo’s providers screen for hypertension, dyslipidemia, andother cardiovascular risk factors, monitoring hematocrit and cardiovascularmarkers throughout treatment.
Medication interactions become more likely asmen accumulate prescriptions for other conditions. Luvo’s clinical team reviewsall current medications to avoid interactions and optimize the treatment plan.
Sleep apnea screening is important becausetestosterone therapy can theoretically worsen untreated obstructive sleep apnea.If sleep apnea is suspected, your Luvo provider will recommend evaluationbefore or alongside testosterone optimization.
Luvo’s testosterone program is designed forthe complexity that men over 40 bring to the table. Rather than a simplified,one-size-fits-all protocol, our providers create individualized treatment plansthat account for your full health picture.
The process starts with a comprehensive healthassessment and bloodwork review. Your provider will determine whether TRT,Enclomiphene, Gonadorelin, or a combination is the right approach for yourhormonal profile, symptoms, and goals.
Ongoing monitoring ensures your treatmentstays safe and effective over time, with dose adjustments and protocol refinementsbased on your response. This isn’t a set-it-and-forget-it prescription — it’san evolving clinical relationship designed to keep you at your best.
The men who thrive on Luvo’s program are thosewho approach it as a long-term investment in their health — not a quick fix.And the results — more energy, better body composition, sharper thinking,stronger libido, and improved mood — are well worth the investment.
Explore Luvo’s testosterone program to getstarted, or learn about our medication options: testosterone medication,Enclomiphene, and Gonadorelin.
Most men who seek testosterone optimizationknow one thing: their T is low and they want it higher. That’s a reasonablestarting point, but the how of raising testosterone matters enormously.Different treatments work on different parts of the hormonal system, withdifferent consequences for fertility, long-term health, and treatmentsustainability.
Understanding thehypothalamic-pituitary-gonadal (HPG) axis — the system that controlstestosterone production — is the key to understanding why Luvo offers threedistinct medications and why the right choice depends on where your system isfailing.
Testosterone production is controlled by athree-level signaling cascade.
Level one is the hypothalamus. This brainstructure produces gonadotropin-releasing hormone (GnRH) in a pulsatile pattern— roughly every 60–90 minutes. The pulsatile nature of GnRH release iscritical; continuous GnRH exposure actually suppresses the pituitary ratherthan stimulating it.
Level two is the anterior pituitary gland. Inresponse to pulsatile GnRH, the pituitary releases two gonadotropins:luteinizing hormone (LH), which stimulates the Leydig cells in the testes toproduce testosterone, and follicle-stimulating hormone (FSH), which stimulatesthe Sertoli cells to support sperm production.
Level three is the testes. Leydig cellsreceive the LH signal and synthesize testosterone from cholesterol through aseries of enzymatic conversions. The testosterone enters the bloodstream andexerts its effects throughout the body. Sertoli cells, stimulated by FSH,create the environment necessary for spermatogenesis.
The system is regulated by negative feedback:testosterone (and its metabolite estradiol) signal back to the hypothalamus andpituitary, modulating GnRH, LH, and FSH output to maintain homeostasis. Whenthe system works properly, testosterone levels are maintained within afunctional range.
Low testosterone can result from failure atdifferent levels of the HPG axis, and identifying where the problem lies isessential for choosing the right treatment.
Primary hypogonadism means the testesthemselves are failing. Despite adequate LH and FSH signaling, the Leydig cellscan’t produce sufficient testosterone. In this case, LH and FSH levels are elevated(the pituitary is working harder to compensate) while testosterone remains low.Causes include testicular injury, genetic conditions like Klinefelter syndrome,and age-related Leydig cell decline.
Secondary hypogonadism means the problem isupstream — the hypothalamus or pituitary isn’t sending adequate signals. LH andFSH levels are low or inappropriately normal, and the testes aren’t beingstimulated to produce testosterone. This is the more common pattern inage-related testosterone decline, obesity-related low T, and stress-inducedhormonal suppression.
Mixed hypogonadism involves dysfunction atmultiple levels — both reduced signaling and reduced testicular response. Thisis increasingly common in older men.
Luvo’s providers use comprehensive bloodworkto identify which pattern is present, because the answer directly determinesthe optimal treatment strategy.
Each medication in Luvo’s testosterone programintervenes at a different point in the HPG axis, which is why having all threeavailable is a clinical advantage.
Testosterone medication works at the end ofthe chain, directly replacing the hormone the testes aren’t producing enoughof. It’s the most direct and potent approach — it reliably raises testosteroneregardless of where the system is failing. The trade-off is that exogenoustestosterone suppresses the upstream signaling (GnRH, LH, FSH), leading totesticular suppression.
Enclomiphene works at the top of the chain, atthe hypothalamic level. By blocking estrogen’s negative feedback, it increasesGnRH output, which increases LH and FSH, which stimulates the testes to producemore testosterone naturally. This preserves the entire axis but depends on thetestes being capable of responding to increased stimulation.
Gonadorelin works at the middle of the chain,directly stimulating the pituitary to release LH and FSH. It’s most valuable asan adjunct to TRT, replacing the GnRH signal that exogenous testosteronesuppresses and maintaining testicular function during testosterone replacement.
This three-level approach is what makes Luvo’sprogram unique. Rather than offering one solution for every patient, we matchthe intervention to the level of the HPG axis where it’s most needed. Exploreall three options: testosterone medication, Enclomiphene, and Gonadorelin.
When a telehealth clinic offers only TRT withno alternatives, they’re giving every man the same tool regardless of where hissystem is failing. A man with secondary hypogonadism (a signaling problem)might respond beautifully to Enclomiphene, preserving his fertility andmaintaining a functional HPG axis — but if TRT is the only option, he’ll getexogenous testosterone and all the suppressive effects that come with it.
Conversely, a man with primary hypogonadismwon’t respond well to Enclomiphene because his testes can’t increase productioneven with more LH stimulation. He needs testosterone replacement, ideally withGonadorelin to preserve what testicular function remains.
Luvo’s diagnostic approach identifies whichscenario applies to you, and our three-medication toolkit ensures you get thetreatment that matches your physiology — not just the treatment that’s easiestto prescribe.
Visit Luvo’s testosterone program to startwith a comprehensive hormonal evaluation.